the placenta (SLC13A4) and maternal kidneys (SLC13A1) screened using DNA sequencing. Infants assessed at 3mth C.A. using General Movements assessment, and at 24mth C.A. using Bayley Scale of Infant and Toddler Development (BSITDIII).
Background: Retinopathy of prematurity (ROP) is a common proliferative retinal vascular disease in babies born very preterm. This study investigated the effects of ROP on long-term visual development.
Methods: The Examining Young Eyes for Signs of PrematuritY (EYE-SPY) study was a prospective, observational study of visual outcomes in children born at <30 weeks GA or <1250g and screened for ROP (children without previous ROP, 'No ROP'; children with previous ROP, 'ROP'; according to International Classification of ROP). A term cohort (GA ≥38 weeks) were also recruited ('Control'). Composite overall, binocular and functional visual outcomes were assessed at 8-10 years of age; including visual acuity, refractive error, ocular alignment and movement, and stereoacuity. Data were analysed using Mann U Whitney (median, IQR) and Chi-squared tests (percentages).
Results: 101 children were assessed (ROP, n=47, No ROP, n=17, Control, weeks)) at 8.8(8.5, 9.0) v 8.9(8.7, 9.4) v 9.2(8.8, 10.1) years (p<0.01). Favourable overall visual outcome were similar between the groups (21/44(48%) v 8/14(29%) v 20/32(63%) p=0.43). Binocular function was poorer in the No ROP group compared to the term group (22/45(49%) v 5/17(29%) v 24/36 (67%) p=0.03), but no longer significant after adjustment for age at assessment (p=0.09). Functional visual outcome tended to be poorer in the ROP group compared to the term group (33/46 (72%) v 14/17(83%) v 33/36(92%) p=0.07).
Conclusions: Children with ROP had better visual outcomes than previously reported but remain at risk of adverse visual outcomes. Preterm children who do not develop ROP also are at risk of visual impairment. Methods: Multicentre, randomised, non-inferiority trial in 9 Australian level 4 SCNs. Eligible infants: ≥31 weeks gestation, birth weight ≥1200 g, <24 hrs old, requiring non-invasive respiratory support, or oxygen for >1 hr. Infants randomised to HF 6 L/ min (max 8) or bubble CPAP 6 cmH 2 O (max 8). Primary outcome: treatment failure within 72 hrs, defined by objective oxygenation, blood gas, and apnoea criteria, or need for urgent intubation or NICU transfer. Infants in the HF group who had treatment failure could receive 'rescue' CPAP. Using a risk difference for the primary outcome of 10% as the non-inferiority margin, a sample size of 750 infants was required.
Results: 754 infants were included in the primary intentionto-treat analysis: 381 HF and 373 CPAP. Demographics of the groups were similar. Treatment failure was more common in the HF group: HF 78/381 (20.5%) vs. CPAP 38/373 (10.2%), risk difference (95% CI) 10.3% (5.2%-15.4%), P=0.0001. There were no differences in rates of intubation or NICU transfer. The HF group received respiratory support for 5 hrs longer, but there was no difference in days of hospitalisation. The rate of pneumothorax requiring drainage was not significantly different.
Conclusion: HF is inferior to CPAP at preventing treatment failure when used as early respiratory support for newborn infants in Australian SCNs. However, when rescue CPAP is available there is no increase in intubation, NICU transfer, or duration of hospitalisation.
DIETARY INTERVENTION AND/OR PROBIOTIC CAPSULES IN OBESE PREGNANT WOMEN-EFFECT ON GESTATIONAL WEIGHT GAIN AND INFANT BIRTHWEIGHT: HEALTHY MUMS AND BABIES (HUMBA) TRIAL

